Praxis Precision Medicines, Inc. Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc.

PRAX

Rangering i aksjer #2585
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Aksjekurs
$264.54
Sist synkronisert: 2026-10-20
Markedsverdi
$7.39B
Endring (1 dag)
1.68%
Endring (1 år)
39.22%
Land
US
Handel Praxis Precision Medicines, Inc. (PRAX)

Kategori

Healthcare
Historikk for aksjesplitt for Praxis Precision Medicines, Inc. (PRAX)
Aksjen Praxis Precision Medicines, Inc. (symbol: PRAX) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Nov 29, 2023.
Én PRAX-aksje kjøpt før Nov 29, 2023 tilsvarer i dag 0.066666666666667 PRAX-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
2023-11-29 1:15 x0.066666666666667 x0.066666666666667
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL